Veru Stock News

The consensus price target hints at a 343.6% upside potential for Veru Inc. (VERU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

-- Phase 3 ENABLAR-2 Clinical Trial for 2nd Line Treatment of AR+ER+HER2- Metastatic Breast Cancer Expected to Commence During First Quarter of 2022 -- MIAMI, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Veru

The FDA has granted Fast Track designation to Veru Inc''s (NASDAQ: VERU ) sabizabulin, oral cytoskeleton disruptor, to combat COVID-19 infection and the cytokine storm responsible for Acute Respiratory Distress Syndrome (ARDS) and death. Sabizabulin disrupts microtubule intracellular transport of the coronavirus, a process that new COVID-19 variants or strains will still require to cause infection. The Company notes that … Full story available on Benzinga.com

Veru''s (VERU) sabizabulin was granted the U.S. Food and Drug Administration''s fast track designation to treat hospitalized patients with COVID-19 who are at high risk for acute…

-- Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitalized Moderate to Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome Being Conducted in US, Mexico, So

The FDA has granted Fast Track designation to Veru Inc's VERU sabizabulin, oral cytoskeleton disruptor, to combat COVID-19 infection and the cytokine storm responsible for Acute Respiratory Distre

MIAMI, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,

MIAMI, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, to

The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.

The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.

The company wins Fast Track designation for a top pipeline program.

The company wins Fast Track designation for a top pipeline program.

Gainers TSR, Inc. (NASDAQ: TSRI ) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year. Accolade, Inc. (NASDAQ: ACCD ) gained 27.3% to $24.36 after the company reported Q3 earnings results and raised FY22 sales guidance. Nuverra Environmental Solutions, Inc. (NYSE: NES ) shares jumped 22.6% to $2.8450. BARK, Inc. (NYSE: BARK ) gained 18% to $4.25. The company said it expects Q3 sales of $140 million, versus analysts’ estimates of $137.3 million. BARK co-founder and executive chairman Matt Meeker will cecome CEO. Nutriband Inc. (NASDAQ: NTRB ) jumped 17.2% to $7.08. Nutriband and Kindeva Drug Delivery, on Monday, signed a feasibility agreement to develop AVERSA Fentanyl, an abuse deterrent fentanyl patch. Veru Inc. (NASDAQ: VERU ) surged 17% to $6.25. Veru, on Monday, said that its Enobosarm was granted fast track designation by the FDA. Cingulate Inc. (NASDAQ: CING ) jumped 15% to $2.82. Aegis Capital initiated coverage on Cingulate with a Buy rating and announced a price target of $9.